Payers have long maintained that the high cost of biologics relative to small-molecule drugs is unsustainable and a threat to their business model. However, a new analysis shows that many plans aren’t yet sold on giving less expensive biosimilars better footing on formularies compared to reference products.
We are excited to announce that PRECISIONvalue has been named a finalist for the 2023 MM+M awards in the Branded Website for Healthcare Professionals category.
We are thrilled to announce that PRECISIONvalue has been named a Market Access Agency of the Year finalist for the 2023 MM+M awards!
As we transition to a different phase of the COVID-19 pandemic, the need for multistakeholder collaboration continues in order to build resilience and prevent or mitigate future pandemics. Precision's Cynthia Miller identifies steps life science companies can take now with other stakeholder partners.
Two important trends that may lead to decreased access to healthcare in the future and worsening disparities. Precision's Cynthia Miller discusses how we got here and a pathway forward.
We are excited to announce that PRECISIONvalue has been named a finalist in the Medical Conference or Event Marketing category of the Fierce Pharma Marketing Awards.
We are excited to announce that PRECISIONvalue has been named a finalist in the Innovation Challenge category of the Fierce Pharma Marketing Awards.
With the end of the COVID-19 Public Health Emergency and national emergency on May 11, 2023, Medicaid state agencies have begun the process of redetermining which Medicaid participants may no longer be eligible and, consequently, dropped from Medicaid. Precision's Jorge Font addresses the potential impact to commercial/employer plan enrollment shifts resulting from the unwinding of Medicaid continuous coverage protection.
As the Biden Administration looked to transition COVID-19 policies, including flexibilities enabled by the COVID-19 emergency declarations, into improving standards of care for patients, it allowed the Public Health Emergency (PHE) Act to expire on May 11, 2023. Precision's Christy Banach considers how the end of the PHE Act will impact care delivery and patient care now that certain provisions that allowed for expanded, easier access to care may or may not remain in place.
We're honored to announce that PRECISIONvalue ranked in MM+M's Top 100 North American healthcare agencies of 2023.
The Precision Value & Health family of brands is now Precision AQ
Precision AQ helps life sciences companies navigate the complexities of commercialization across a product’s lifecycle. Our team is comprised of experts, advisors, and creators working to ensure patients have access to life-changing medicines.
Our global offerings include:
Our name, which stands for Precision Access Quotient, reflects our approach to removing barriers – fusing together science (IQ, or Intelligence Quotient) and empathy (EQ, or Emotional Quotient). The result is “AQ: Access Quotient”, a critical ingredient in navigating the therapy-to-patient journey informed by data-driven analytics and insights.
To find out more about our global services and our unified mission, empowering access to life-changing medicines for all, visit: Precision AQ
